<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294160</url>
  </required_header>
  <id_info>
    <org_study_id>CADPT01C12101</org_study_id>
    <nct_id>NCT04294160</nct_id>
  </id_info>
  <brief_title>A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer</brief_title>
  <official_title>A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase Ib, open-label platform study of select drug combinations chosen in order to
      characterize safety and tolerability of each treatment arm tested and to identify recommended
      doses and regimens for future studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase Ib, multi-center, open-label study with multiple treatment arms in adult
      patients with advanced or metastatic BRAF V600 (E, D, or K) in order to characterize safety
      and tolerability of each treatment arm tested and to identify recommended doses and regimens
      for future studies. The open platform design of this study is adaptive to allow removal of
      combination treatment arm(s) based on emerging data and facilitate introduction of new
      candidate combinations. The study is comprised of a dose escalation part and may be followed
      by a dose expansion part for any combination treatment arm.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 22, 2020</start_date>
  <completion_date type="Anticipated">February 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 27, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs) in the first cycle</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize safety and tolerability of each treatment arm tested and identify recommended doses (RD) and regimens for future studies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of AEs and SAEs, including changes in laboratory values, vital signs, and ECGs</measure>
    <time_frame>34 months</time_frame>
    <description>To characterize safety and tolerability of each treatment arm tested and identify recommended doses and regimens for future studies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose interruptions</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize safety and tolerability of each treatment arm tested and identify recommended doses and regimens for future studies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose reductions</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize safety and tolerability of each treatment arm tested and identify recommended doses and regimens for future studies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize safety and tolerability of each treatment arm tested and identify recommended doses and regimens for future studies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast derived from Serum/plasma concentration of individual investigational drugs within combination treatments</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize the PK of each investigational drug within each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>34 months</time_frame>
    <description>To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>34 months</time_frame>
    <description>To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>34 months</time_frame>
    <description>To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>34 months</time_frame>
    <description>To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>34 months</time_frame>
    <description>To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of the PD marker DUSP6 in tumor tissue (dose escalation only)</measure>
    <time_frame>30 months</time_frame>
    <description>To evaluate PD effect in their respective combinations in tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau derived from Serum/plasma concentration of individual investigational drugs within combination treatments</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize the PK of each investigational drug within each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax derived from Serum/plasma concentration of individual investigational drugs within combination treatments</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize the PK of each investigational drug within each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax derived from Serum/plasma concentration of individual investigational drugs within combination treatments</measure>
    <time_frame>30 months</time_frame>
    <description>To characterize the PK of each investigational drug within each treatment arm</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>BRAF V600 Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Dabrafenib + LTT462 backbone arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabrafenib + LTT462 + trametinib triplet arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabrafenib + LTT462 + LXH254 triplet arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabrafenib + LTT462 + TNO155 triplet arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabrafenib + LTT462 + spartalizumab triplet arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>Capsule for oral use</description>
    <arm_group_label>Dabrafenib + LTT462 + LXH254 triplet arm 2</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 + TNO155 triplet arm 3</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 + spartalizumab triplet arm 4</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 + trametinib triplet arm 1</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 backbone arm 1</arm_group_label>
    <other_name>DRB436, Tafinlar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTT462</intervention_name>
    <description>Capsule for oral use</description>
    <arm_group_label>Dabrafenib + LTT462 + LXH254 triplet arm 2</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 + TNO155 triplet arm 3</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 + spartalizumab triplet arm 4</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 + trametinib triplet arm 1</arm_group_label>
    <arm_group_label>Dabrafenib + LTT462 backbone arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>Tablet for oral use</description>
    <arm_group_label>Dabrafenib + LTT462 + trametinib triplet arm 1</arm_group_label>
    <other_name>TMT212, Mekinist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LXH254</intervention_name>
    <description>Tablet for oral use</description>
    <arm_group_label>Dabrafenib + LTT462 + LXH254 triplet arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TNO155</intervention_name>
    <description>Capsule for oral use</description>
    <arm_group_label>Dabrafenib + LTT462 + TNO155 triplet arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Spartalizumab</intervention_name>
    <description>Liquid in vial (Concentrate for solution for infusion) for intravenous use</description>
    <arm_group_label>Dabrafenib + LTT462 + spartalizumab triplet arm 4</arm_group_label>
    <other_name>PDR001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with unresectable advanced/metastatic BRAF V600 cancer of the colon or rectum
             with measurable disease as determined by RECIST v1.1

          -  Patients must have a site of disease amenable to biopsy, and be a candidate for tumor
             biopsy according to the treating institution's guidelines. Patients must be willing to
             undergo a new tumor biopsy at baseline and during therapy on study.

        Exclusion Criteria:

          -  Has a known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy, or in-situ cervical cancer, or
             other tumors that will not affect life expectancy.

          -  Current evidence/known risk of uveitis in the opinion of the investigator

          -  A history of or current evidence/risk of retinal vein occlusion (RVO) or serous
             retinopathy

          -  History of or current interstitial lung disease or non-infectious pneumonitis

          -  Patients with a history of diabetes requiring medical therapy that is not
             well-controlled on a stable regimen in the opinion of the investigator

          -  Insufficient bone marrow function prior to start of treatment

          -  Insufficient hepatic or renal function prior to start of treatment

          -  Patients who have potassium, magnesium, calcium (corrected for serum albumin), or
             phosphate laboratory values outside of the laboratory normal limits

          -  Patients with active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

          -  Patients with known history of testing positive for Human Immunodeficiency Virus
             (HIV).

          -  Clinically significant cardiac disease at screening

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase Ib, BRAF-mutated, BRAF V600E, BRAF V600D, BRAF V600K, colorectal cancer, colon cancer, rectal cancer, metastatic, BLRM with EWOC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

